Current And Future Valuation 2025, page-186

I''m frustrated with the 'pump and dump' like performance of the BOT share price so I've gathered some background information to get a feel of it's potential and the inherent risks. Here's a brief summary from which you can draw your own conclusions..My major concern is that all will be fine as long as it continues to to be the only effective (go-to )treatment, that said if it prescribed to the extent that it becomes a major cost factor then insurers will likely take steps to make it more difficult to claim..In my view it is reasonable to expect the share price.to be 3X or even 5X current value so $1.50 to $2.50 as conservative estimates
Strong market protection: No FDA-approved generics until at least 2031 (exclusivity) and possibly until 2040 (patents).
Only FDA-approved treatment: Likely to be covered by insurers due to medical necessity.:
May appear on higher tiers, resulting in higher co-payments.
Cost-control strategies: Insurers may require prior authorization or step therapy.
Public insurance coverage: Medicaid and Medicare typically cover it, though restrictions may apply by state.High pricing expected:
Prices likely to stay high and may increase over time.Access depends on insurance:
Well-insured patients may get coverage, but affordability could be a barrier for the uninsured or under-insured.